Health Care Distributors

Jointown

Jointown released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 44.78 B (forecast CNY 39.05 B), actual EPS CNY 0.14 (forecast CNY 0.1646)

Jointown released FY2025 Annual Earnings on April 27 Pre-Market (BJT), actual revenue CNY 161.39 B (forecast CNY 161.98 B), actual EPS CNY 0.44 (forecast CNY 0.5269)

Jointown released FY2025 Q4 earnings on April 27 Pre-Market (BJT), actual revenue CNY 42.06 B (forecast CNY 41.3 B), actual EPS CNY 0.0526 (forecast CNY 0.1345)

Jointown to Release FY2026 Q1 Earnings on April 28 After-Market (BJT), Forecast Revenue CNY 39.05 B, EPS CNY 0.1646

Jointown to Release FY2025 Annual Earnings on April 28, Pre-Market BJT; Forecast Revenue CNY 161.98 B, EPS CNY 0.5269

Jointown released FY2025 9 Months Earnings on October 27 After-Market BJT, actual revenue CNY 119.33 B, actual EPS CNY 0.3891

Jointown released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 38.22 B (forecast CNY 41.76 B), actual EPS CNY 0.1013 (forecast CNY 0.0979)

Jointown to release FY2025 Q3 earnings on October 28 After-Market (BJT), forecast revenue CNY 41.76 B, EPS CNY 0.0979

Jointown released FY2025 Semi-Annual earnings on August 26 After-Market (BJT), actual revenue CNY 81.11 B, actual EPS CNY 0.29

Jointown released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 39.09 B (forecast CNY 38.28 B), actual EPS CNY 0.0977 (forecast CNY 0.1318)

Jointown FY2025 Semi-Annual Earnings Release on August 27, 2025 (BJT)

Jiuzhoutong Health Development Co., Ltd Established

Chongqing Jiuzhou Yaoyang New Energy Co., Ltd. Established

Jiuzhou Tong's Subsidiary Obtains Dexamethasone Sodium Phosphate Injection Drug Registration Certificate

Jiuzhou Tong's Subsidiary Huiyu Yuanhe Obtains Registration Certificate for Betamethasone Sodium Phosphate Injection

Jiuzhoutong Establishes Early-stage Pharmaceutical Project Fund

Jiuzhou Tong Subsidiary Establishes Venture Capital Partnership

Jiuzhou Tong Medical Device Supply Chain Co., Ltd. Established

Analysts at China Post Securities Give Jiumutong a Buy Rating

KBAB

BABX

09988

BABA

600998

Taobao Flash Sale recently launched China's first instant retail medical and health warehouse system. It has partnered with Jointown Medical Devices Group, a domestic pharmaceutical distribution giant, and several leading medical brands to complete the initial implementation of this model

Wallstreetcn

KraneShares 2x Long BABA Daily ETF

BABA 2x Long Daily ETF - GraniteShares

BABA-W

Alibaba

Taobao Flash Sale Increases Investment in Healthcare, Partnering with Jointown to Create "Ma Shang Jiu Song" New Warehouse-Store Model

300937

301017

603233

603883

603939

Pharmaceutical commercial stocks opened higher, with Yifeng Pharmacy hitting the daily limit, followed by DSL, Jointown, Hezong Medicine Easy-To-Buy Pharmaceutical, SYPM, and LBX. In terms of news, the Ministry of Commerce and 8 other departments issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry."

Hezong Medicine Easy-To-Buy Pharmaceutical

SYPM

Yifeng Pharmacy

According to the Qichacha APP, recently, Liaoning Jointown Supply Chain Management Co., Ltd. was established, with Liu Lanfang as the legal representative, a registered capital of 20 million yuan, and a business scope that includes supply chain management services, import and export of goods, and operation of Class III medical devices. The equity penetration of Qichacha shows that the company is jointly held by Jointown's subsidiary, Jointown Medical Device Group Co., Ltd., among others

Zhitong

Jointown and others establish a new supply chain management company in Liaoning

According to the Qichacha APP, recently, Jiuzhou Industrial Investment Operation Management Co., Ltd. was established, with Su Xiling as the legal representative and a registered capital of 10 million yuan. The business scope includes enterprise management; technology intermediary services; project management services; park management services; enterprise management consulting; information technology consulting services, etc. Qichacha's equity penetration shows that the company is wholly owned by Jiuzhou Tong indirectly

Jointown established a production investment operation management company in Hengqin

Jointown announced that its subsidiary Beijing Jingfeng Pharmaceutical Group's subsidiary Huili Yuanyuan Pharmaceutical Co., Ltd. received the "Drug Supplement Application Approval Notice" approved and issued by the National Medical Products Administration on October 24, 2025, approving the change of the marketing authorization holder for dopamine hydrochloride injection to Huili Yuanyuan. This drug is mainly used for shock syndromes caused by myocardial infarction, trauma, and other conditions, as well as heart failure. In 2024, the sales of dopamine hydrochloride injection in hospitals reached 175 million yuan

Jointown: The holder of the marketing authorization for Dopamine Hydrochloride Injection has been changed to Huiyu Yuanhe

Jointown announced that its revenue for the third quarter was 38.22 billion yuan, a year-on-year increase of 5.41%; net profit was 530 million yuan, a year-on-year increase of 8.46%. Revenue for the first three quarters was 119.327 billion yuan, a year-on-year increase of 5.20%; net profit was 1.975 billion yuan, a year-on-year increase of 16.46%

Jointown: Net profit in the third quarter was 530 million yuan, a year-on-year increase of 8.46%

According to the Tianyancha App, recently, Henan Jointown Medical Equipment Co., Ltd. was established, with Li Wa as the legal representative and a registered capital of 10 million RMB. The business scope includes the sale of Class I medical devices, the sale of Class II medical devices, and the rental of Class I medical equipment, among others. Shareholder information shows that the company is jointly held by Jointown Medical Equipment Group Co., Ltd. and Henan Beijia Enterprise Management Consulting Co., Ltd

Jointown Medical Devices Group and others established a new company in Henan with a registered capital of 10 million

Jointown's subsidiary Beijing Jingfeng Pharmaceutical has received approval from the National Medical Products Administration for the market application of the chemical raw material drug, Glycopyrrolate. This drug is a quaternary ammonium anticholinergic agent primarily used for the treatment of gastric and duodenal ulcers, chronic gastritis, and chronic obstructive pulmonary disease, with the effects of inhibiting gastric acid secretion and dilating airways

Jointown: Gelong Bromide has received approval for the listing application of chemical raw materials

Jointown announced that its holding subsidiary Beijing Jointown Zhongchuang Technology Incubator Co., Ltd. has committed to contribute 10 million yuan as a limited partner to establish the Wuhan Chuchang Tongda Industrial Investment Fund, holding a 7.14% share. The fund's executive managing partner and other limited partners are all subsidiaries of the company's controlling shareholder Chuchang Investment Group, therefore this investment constitutes a related party transaction but does not constitute a major asset reorganization

Jointown: The holding subsidiary participates in the establishment of an industrial fund, holding a 7.14% share

Jointown(600998.SH)